Ledoxantrone,alsoknownassedoxantroneorCI-958,isananthrapyrazoleantineoplasticantibioticmoleculewithpotentialantineoplasticactivity.SedoxantroneintercalatesintoDNAandinteractswithtopoisomeraseII,therebyinhibitingDNAreplicationandrepairandRNAandproteinsynthesis.Checkforactiveclinicaltrialsorclosedclinicaltrialsusingthisagent.(NCIThesaurus)

MedKooCat#:205993
Name:Ledoxantrone
CAS#:113457-05-9
ChemicalFormula:C21H27N5OS
ExactMass:397.19363
MolecularWeight:397.53698
ElementalAnalysis:C,63.45;H,6.85;N,17.62;O,4.02;S,8.07


Synonym:Ledoxantrone;sedoxantrone;CI958;CI-958;CI958

IUPAC/ChemicalName:5-((2-aminoethyl)amino)-2-(2-(diethylamino)ethyl)-2H-thiochromeno[4,3,2-cd]indazol-8-ol

InChiKey:HPCHDLLMIWHKBW-UHFFFAOYSA-N

InChiCode:InChI=1S/C21H27N5OS/c1-3-25(4-2)11-12-26-17-8-7-16(23-10-9-22)21-19(17)20(24-26)15-6-5-14(27)13-18(15)28-21/h5-8,13,23,27H,3-4,9-12,22H2,1-2H3

SMILESCode:OC1=CC(S2)=C(C3=NN(CCN(CC)CC)C4=C3C2=C(NCCN)C=C4)C=C1


TechnicalData

Appearance:
Solidpowder

Purity:
>98%

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>5yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

  
 
 
 


References

1:BrauerCA,Coca-PerraillonM,CutlerDM,RosenAB.IncidenceandmortalityofhipfracturesintheUnitedStates.JAMA.2009Oct14;302(14):1573-9.doi:10.1001/jama.2009.1462.PubMedPMID:19826027.

2:PhilipKueblerJ,MooreT,PritchardJ,KrautE.PhaseIIstudyofCI-958inpatientswithhormonerefractoryprostatecarcinoma.InvestNewDrugs.2004Apr;22(2):181-4.PubMedPMID:14739667.

3:HoffmanMA,BlessingJA,NuñezER.AphaseIItrialofCI-958inrecurrentplatinum-sensitiveovariancarcinoma:aGynecologicOncologyGroupstudy.GynecolOncol.2001Jun;81(3):433-5.PubMedPMID:11371134.

4:ArndtCA,KrailoMD,Liu-MaresW,AndersonPM,ReamanGH.PhaseIstudyofCI-958inchildrenandadolescentswithrecurrentsolidtumors.Cancer.2001Mar15;91(6):1166-9.PubMedPMID:11267962.

5:HoffPM,EllertonJA,DakhilSR,WinnRJ,AbbruzzeseJL,PazdurR.PhaseIIstudyofintravenousCI-958inmetastaticcolorectaladenocarcinoma.AmJClinOncol.2000Dec;23(6):602-4.PubMedPMID:11202806.

6:HoffmanMA,BlessingJA,MorganM.PhaseIItrialofCI-958inrecurrentplatinum-refractoryovariancarcinoma.AGynecologicOncologyGroupStudy.GynecolOncol.2000Dec;79(3):463-5.PubMedPMID:11104620.

7:DeesEC,WhitfieldLR,GroveWR,RummelS,GrochowLB,DonehowerRC.AphaseIandpharmacologicevaluationoftheDNAintercalatorCI-958inpatientswithadvancedsolidtumors.ClinCancerRes.2000Oct;6(10):3885-94.PubMedPMID:11051234.

8:WoolleyPV,FreihaFS,SmithDC,CarlsonL,HofackerJ,QuinnN,GroveW,TrumpDL.AphaseIItrialofCI-958inpatientswithhormone-refractoryprostatecancer.CancerChemotherPharmacol.1999;44(6):511-7.PubMedPMID:10550573.

9:ShieldsAF,PhilipPA,LoRussoPM,FerrisAM,ZalupskiMM.PhaseIIstudyofCI-958incolorectalcancer.CancerChemotherPharmacol.1999;43(2):162-4.PubMedPMID:9923823.

10:LunL,SunPM,TrubeyCM,BachurNR.AntihelicaseactionofCI-958,anewdrugforprostatecancer.CancerChemotherPharmacol.1998;42(6):447-53.PubMedPMID:9788570.

11:KayeSB,WorkmanP,GrahamMA,CassidyJ,JodrellD.Pharmacokineticsandearlyclinicalstudiesofselectednewdrugs.CancerSurv.1993;17:371-96.Review.PubMedPMID:8137348.

12:FryDW,BessererJA.BiochemicalpharmacologyandDNA-druginteractionsbyCl-958,anewantitumorintercalatorderivedfromaseriesofsubstituted2H-[1]benzothiopyrano[4,3,2-cd]indazoles.MolPharmacol.1988Jan;33(1):84-92.PubMedPMID:2447481.